Related Experiment Video

Updated: Aug 8, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Efficacy of different schedules in the management of chronic hepatitis C with interferon-alpha

M Malaguarnera1, I Di Fazio, S Restuccia

  • 1Department of Internal Medicine and Geriatrics, University of Catania, Italy. malaguar@mbox.unict.it

Annals of Medicine
|July 17, 1998
PubMed

Insights

Interferon (IFN)-alpha therapy for chronic hepatitis C showed varying remission rates. Longer treatment durations did not significantly improve outcomes or patient adherence compared to shorter, less intensive schedules.

Area of Science:

  • Hepatology
  • Virology
  • Clinical Medicine

Background:

  • Chronic hepatitis C (HCV) infection remains a significant global health concern.
  • Interferon (IFN)-alpha therapy has been a cornerstone treatment for HCV, aiming for clinical remission.
  • Optimizing IFN-alpha treatment regimens is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of different interferon (IFN)-alpha therapeutic schedules in patients with chronic hepatitis C.
  • To determine the optimal duration and dosage of IFN-alpha for achieving sustained virological and biochemical remission.
  • To assess the impact of treatment intensity on patient response and compliance.

Main Methods:

  • A study involving 255 patients with chronic hepatitis C infection (HCV).
  • Patients were divided into three groups receiving distinct IFN-alpha treatment regimens: Group A (3 MU thrice weekly for 6 months), Group B (3 MU thrice weekly for 12 months), and Group C (6 MU thrice weekly for 6 months).
  • Outcomes were assessed based on sustained biohumoural and virological remission rates.

Main Results:

  • Sustained remission was observed in 14.5% of patients in Group A, 21.6% in Group B, and 8% in Group C.
  • More aggressive therapeutic regimens (higher dose or longer duration) did not lead to improved response rates.
  • Patient compliance did not improve with more intensive treatment schedules.

Conclusions:

  • The 12-month treatment schedule (Group B) demonstrated a slightly higher sustained remission rate compared to shorter or more intensive regimens.
  • Increasing the intensity of interferon (IFN)-alpha therapy does not necessarily enhance clinical remission or patient compliance in chronic hepatitis C.
  • Long-term efficacy of HCV treatment should be evaluated using both biochemical and virological markers.

More Related Videos

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...